We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Japanese Researchers Demonstrate Novel Transcutaneous Influenza Vaccination Using a Dissolving Microneedle Patch

By LabMedica International staff writers
Posted on 27 Jul 2015
Print article
Image: The microneedle patch can dissolve in the skin, delivering the flu vaccine painlessly (Photo courtesy of Dr. Shinsaku Nakagawa, Osaka University).
Image: The microneedle patch can dissolve in the skin, delivering the flu vaccine painlessly (Photo courtesy of Dr. Shinsaku Nakagawa, Osaka University).
Image: The microneedle patch can dissolve in the skin, delivering the flu vaccine painlessly (Photo courtesy of Dr. Shinsaku Nakagawa, Osaka University).
Image: The microneedle patch can dissolve in the skin, delivering the flu vaccine painlessly (Photo courtesy of Dr. Shinsaku Nakagawa, Osaka University).
Vaccination via a biodegradable microneedle patch was shown to generate immune response to various strains of the influenza virus that were equal to or stronger than those induced by traditional hypodermic needle injection.

Previous attempts using microneedles made of silicon or metal were not successful primarily due to the risk of the needles breaking off in the skin, leaving tiny fragments behind. To avoid this problem, investigators at Osaka University (Japan) prepared microneedle patches from hyaluronic acid, a naturally occurring and water soluble biological material. The "MicroHyala" microneedle patch was loaded with the material to be injected and then applied like a plaster. The needles pierced the top layer of skin and then dissolved into the body, taking the vaccine with them.

In the current study the investigators examined the clinical safety and efficacy of the MicroHyala vaccination method using MH (flu-MH), which contains trivalent influenza hemagglutinins (15 micrograms each). Subjects were treated transcutaneously (TCI group) with a flu-MH microneedle patch, and were compared with subjects who received subcutaneous injections (SCI group) of a solution containing 15 micrograms of each influenza antigen.

Results published in the July 2015 issue of the journal Biomaterials revealed that no severe local or systemic adverse events were detected in either group. Immune responses against A/H1N1 and A/H3N2 strains were induced equally in the TCI and SCI groups. Moreover, the efficacy of the vaccine against the B strain in the TCI group was stronger than that in the SCI group.

"Our novel transcutaneous vaccination using a dissolving microneedle patch is the only application vaccination system that is readily adaptable for widespread practical use," said senior author Dr. Shinsaku Nakagawa, professor of medical pharmacy at Osaka University. "Because the new patch is so easy to use, we believe it will be particularly effective in supporting vaccination in developing countries."

"We were excited to see that our new microneedle patch is just as effective as the needle-delivered flu vaccines, and in some cases even more effective," said Dr. Nakagawa. "We have shown that the patch is safe and that it works well. Since it is also painless and very easy for non-trained people to use, we think it could bring about a major change in the way we administer vaccines globally."

Related Links:

Osaka University


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Cancer Mutation Profiling Liquid Kit
OncoScreen Plus

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.